In the fiscal year ending December 2024, VIS will promote mRNA-targeted small molecule drug discovery business and the creation of its own pipeline.
Veritas In Silico <130A> announced its fiscal results for the year ending December 2024 on the 13th. Business revenue decreased by 46.0% compared to the previous year to 0.194 billion yen, with an operating loss of 0.212 billion yen (compared to a profit of 0.037 billion yen in the previous term), an ordinary loss of 0.233 billion yen (compared to a profit of 0.035 billion yen in the previous term), and a net loss of 0.236 billion yen (compared to a profit of 0.033 billion yen in the previous term). In the company's mRNA-targeted small molecule drug discovery business, the drug discovery platform ibVIS(R) is being utilized, and TORAY INDS INC <3402>.
Bachuan Corporation --- In the third quarter, revenue increased significantly and net profit saw a large increase, with the toner business and the Semiconductors and Display related businesses performing well.
Bachuan Corporation <3878> announced on the 13th its consolidated financial results for the third quarter of the fiscal year ending March 2025 (April-December 2024). Revenue increased by 4.0% year-on-year to 25.934 billion yen, operating profit rose by 29.3% to 1.264 billion yen, ordinary profit increased by 21.9% to 1.482 billion yen, and the quarterly net profit attributable to shareholders increased by 119.2% to 0.995 billion yen. Regarding the overview of the four main segments, revenue from the toner business increased by 10.0% year-on-year to 94.7.
Stocks that moved or were traded in the first half of the session.
*Takasago International Corporation <4914> 6150 -Significantly revised upward the financial estimates and dividend forecasts. *GMO Internet <4784> 1350 +214 The guidance for this period and expectations for increased dividends continue to have an impact. *PeptiDream <4587> 2343.5 +354 The guidance for increased profits this period is viewed positively. *PKSHA Technology <3993> 4720 +700 The first quarter showed significant profit growth and good progress. *Lion Corporation <4912> 1858.
Haseko, Daiwa House, ETC (additional) Rating
Upgraded - Bullish Code Stock Name Brokerage Firm Previous Change After -------------------------------------------------------- <8056> BIPROGY City "3" "2" Downgraded - Bearish Code Stock Name Brokerage Firm Previous Change After -------------------------------------------------------- <3659> Nexon Nomura "Buy" "
Lion ranks, operating profit is expected to increase by 38% compared to the previous period and by 23% this period, and a medium-term management plan has also been announced.
Lion Corp. <4912> is ranked (as of 9:32 AM). It has surged. After the previous trading day's close, they announced their financial results for the fiscal year ending December 2024. The operating profit is 28.3 billion yen, a 38.4% increase from the previous term. The previous Financial Estimates were 27 billion yen. The operating profit for the fiscal year ending December 2025 is estimated to be 35 billion yen, a 23.3% increase from the previous term. The aim is to establish a highly profitable business portfolio in the consumer goods sector. At the same time, a mid-term management plan was announced, with a target operating profit of 40 billion yen for the fiscal year ending December 2027. Volume change rate ranking.
February 14 [Today's Investment Strategy]
[Fisco Selected Issues] [Material Stock] PKSHA Technology <3993> 4020 yen (2/13) Developing AI Algorithms and implementing them as a product in society. The first quarter financial results were announced. Operating profit was 1.039 billion yen (an increase of 32.5% compared to the same period last year). Acquisition of solution projects in the AI Research & Solution business and expansion of product sales in the AI SaaS business. Revenue from the new group company also contributed.